Evidence map›Paper›PMID 39451318›Full record

ArticleGels (Basel, Switzerland)2024

Development of Personalised Immediate-Release Gel-Based Formulations Using Semi-Solid Extrusion.

Morenikeji Aina, Fabien Baillon, Romain Sescousse, Noelia M Sanchez-Ballester, Sylvie Begu, Ian Soulairol, Martial Sauceau

Abstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Morenikeji AinaRAPSODEE, IMT Mines Albi, CNRS, University of Toulouse, 81013 Albi, France.ORCID 0000-0002-3637-6873
Fabien BaillonRAPSODEE, IMT Mines Albi, CNRS, University of Toulouse, 81013 Albi, France.ORCID 0000-0003-0649-9386
Romain SescousseRAPSODEE, IMT Mines Albi, CNRS, University of Toulouse, 81013 Albi, France.ORCID 0000-0002-0717-0219
Noelia M Sanchez-BallesterICGM, University of Montpellier, CNRS, ENSCM, 34293 Montpellier, France.ORCID 0000-0003-1614-4773
Sylvie BeguICGM, University of Montpellier, CNRS, ENSCM, 34293 Montpellier, France.
Ian SoulairolICGM, University of Montpellier, CNRS, ENSCM, 34293 Montpellier, France.ORCID 0000-0002-8837-5362
Martial SauceauRAPSODEE, IMT Mines Albi, CNRS, University of Toulouse, 81013 Albi, France.ORCID 0000-0002-2709-1016

Funding

Agence nationale de la recherche ANR-18-EURE-0021Occitanie region ANR-18-EURE-0021
6 · The paper itself

Abstract

Precision in dosing is crucial for optimizing therapeutic outcomes and preventing overdosing, especially in preterm infants. Traditional manual adjustments to adapt the dose often lead to inaccuracies, contamination risks, and reduced precision. To overcome these challenges, semi-solid extrusion 3D printing was used to create personalised gel-based caffeine dosage forms. The hydrogels, made from agar and hydroxypropyl methylcellulose, demonstrated excellent rheological properties, ensuring uniform extrusion and accurate shape retention during and after printing. This gel formulation allowed for precise adjustments of caffeine volume and content tailored to a neonate weighing 1.36 kg, achieving a recovery of 103.46%, well within acceptable limits. Additionally, three production batches confirmed the process's reproducibility with minimal variability. Forced degradation studies showed that both pure caffeine and caffeine in the gel matrix exhibited similar stability profiles, confirming the drug's chemical integrity. The printed gel dosage forms also displayed immediate-release characteristics, with over 80% of caffeine released within 45 min, highlighting their suitability for rapid therapeutic action. These findings emphasise the potential of SSE 3DP and gel-based formulations to produce personalised drug delivery systems with high precision, reproducibility, and reliability.

Indexed as

agarbatch variabilitycaffeineforced degradationhydroxypropyl methylcellulose (HPMC)immediate releasepersonalised medicinesemi-solid extrusionstability

Identifiers

PMID39451318
PMCPMC11507880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.